MOUNJARO Drug Patent Profile

Which patents cover Mounjaro, and when can generic versions of Mounjaro launch?

Mounjaro is a drug marketed by Eli Lilly And Co and is included in one NDA. There are six patents protecting this drug.

This drug has two hundred and one patent family members in forty-six countries.

The generic ingredient in MOUNJARO is tirzepatide. One supplier is listed for this compound. Additional details are available on the tirzepatide profile page.

DrugPatentWatch^® Generic Entry Outlook for Mounjaro

Mounjaro will be eligible for patent challenges on May 13, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 5, 2036. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for MOUNJARO

International Patents:	201
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	3
Clinical Trials:	7
Drug Prices:	Drug price information for MOUNJARO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MOUNJARO
What excipients (inactive ingredients) are in MOUNJARO?	MOUNJARO excipients list
DailyMed Link:	MOUNJARO at DailyMed

See drug prices for MOUNJARO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for MOUNJARO

NDA:

215866

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for MOUNJARO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
First Affiliated Hospital of Wenzhou Medical University	PHASE2
Johns Hopkins University	PHASE2
University Medical Centre Ljubljana	PHASE4

See all MOUNJARO clinical trials

Pharmacology for MOUNJARO

Drug Class	GLP-1 Receptor Agonist Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
Mechanism of Action	G-Protein-linked Receptor Interactions Glucagon-like Peptide-1 (GLP-1) Agonists

US Patents and Regulatory Information for MOUNJARO

MOUNJARO is protected by twenty-three US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eli Lilly And Co	MOUNJARO KWIKPEN	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-022	Jan 20, 2026		RX	Yes	Yes			Y	Y
Eli Lilly And Co	MOUNJARO	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-009	Jul 28, 2023		RX	Yes	Yes
Eli Lilly And Co	MOUNJARO	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-013	Jan 7, 2026		RX	Yes	Yes			Y	Y
Eli Lilly And Co	MOUNJARO	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-015	Jan 7, 2026		RX	Yes	Yes			Y	Y
Eli Lilly And Co	MOUNJARO	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-009	Jul 28, 2023		RX	Yes	Yes

EU/EMA Drug Approvals for MOUNJARO

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Eli Lilly Nederland B.V.	Mounjaro	tirzepatide	EMEA/H/C/005620Mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4.4, 4.5 and 5.1.	Authorised	no	no	no	2022-09-15

International Patents for MOUNJARO

When does loss-of-exclusivity occur for MOUNJARO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

El Salvador

Eurasian Patent Organization

European Patent Office

Finland

France

Hungary

Israel

Japan

Jordan

Lithuania

Luxembourg

Malaysia

Mexico

Moldova, Republic of

Montenegro

Morocco

Netherlands

New Zealand

Norway

Peru

Philippines

Poland

Portugal

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering MOUNJARO around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20250090374	GIP/GLP1 작용제 조성물 (GIP/GLP1 GIP/GLP1 AGONIST COMPOSITIONS)
Netherlands	301217
Japan	6219534
Serbia	59146	JEDINJENJA KO-AGONISTI GIP I GLP-1 (GIP AND GLP-1 CO-AGONIST COMPOUNDS)
Ecuador	SP17043648

Supplementary Protection Certificates for MOUNJARO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3242887	23C1006	France		PRODUCT NAME: TIRZEPATIDE; REGISTRATION NO/DATE: EU/1/22/1685 20220919
3242887	CA 2023 00005	Denmark		PRODUCT NAME: TIRZEPATID OG FARMACEUTISK ACCEPTABLE SALTE DERAF; REG. NO/DATE: EU/1/22/1685 20220919
3242887	SPC/GB23/006	United Kingdom		PRODUCT NAME: TIRZEPATIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF.; REGISTERED: UK EU/1/22/1685(FOR NI) 20220919; UK MORE ON HISTORY TAB 20220919
3242887	C202330010	Spain		PRODUCT NAME: TIRZEPATIDA Y SALES FARMACEUTICAMENTE ACEPTABLES DE LA MISMA; NATIONAL AUTHORISATION NUMBER: EU/1/22/1685; DATE OF AUTHORISATION: 20220915; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/22/1685; DATE OF FIRST AUTHORISATION IN EEA: 20220915
3242887	2390005-3	Sweden		PRODUCT NAME: TIRZEPATIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/22/1685, 2022-09-19; RAETTAD SKYDDSTID FOER TILLAEGGSSKYDD'; PRV HAR I BESLUT DEN 8 JULI 2025 RAETTAT SKYDDSTIDEN I FOELJANDE TILLAEGGSSKYDD I ENLIGHET MED PMD:S BESLUT PMAE 7804/24: 2290016-1, 2090020-5, 2090055-1, 1590060-8, 1890030-8, 1990012-5, 2190017-0, 1690040-9, 1790035-8, 2390005-3, 1990013-3, 2090009-8

Market Dynamics and Financial Trajectory for MOUNJARO (Tirzepatide)

Last updated: March 9, 2026

MOUNJARO (tirzepatide) is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. It targets type 2 diabetes mellitus (T2DM), obesity, and weight management indications.

Market Entry and Competitive Landscape

Launch Timeline and Market Position
MOUNJARO received FDA approval for T2DM in May 2022, followed by approval for obesity in June 2023. It positions itself against established drugs such as Novo Nordisk’s Ozempic (semaglutide) and Wegovy (semaglutide).

Market Size and Penetration

• T2DM global market was valued at USD 80 billion in 2021, expected to grow annually at 7%.
• Obesity management market reached USD 13 billion in 2022, projected to grow at 10% CAGR.
• MOUNJARO commands a rapid share gain, driven by superior efficacy in weight reduction and glycemic control.

Competitive Advantages

• Dual hormone mechanism shows greater efficacy in weight loss and glucose lowering than single agonists.
• Early clinical data indicate superiority over semaglutide in reducing HbA1c by 2 percentage points and weight loss by an additional 6-8%.
• Eli Lilly’s established sales infrastructure accelerates adoption.

Challenges

• Established competitors with market share, such as Novo Nordisk’s Ozempic/Wegovy.
• Pricing strategies are under negotiation; high-cost drugs may face reimbursement barriers.
• Long-term safety and real-world effectiveness still under observation.

Revenue Forecast and Sales Projections

Initial Sales Data

• In Q2 2023, sales of MOUNJARO exceeded USD 400 million globally, with about 2 million prescriptions filled within six months of launch (Eli Lilly, 2023).

Market Share Development

• By end of 2023, MOUNJARO is projected to attain a 15% share of the T2DM GLP-1 market.
• For obesity, expected to reach USD 1 billion in sales in 2024, capturing approximately 10% of the total market.

Revenue Estimates (2023-2025)

Year	Estimated Global Sales	Notes
2023	USD 2.2 billion	Rapid uptake in T2DM, early obesity indication sales.
2024	USD 4.5 billion	Market share expansion, new indications.
2025	USD 7.8 billion	Broader insurance coverage, increased adoption.

Pricing Strategy

• Estimated list price per pen: USD 1,100–1,300.
• Discounting and rebates may lower net prices by 20–30%.

Regulatory and Policy Factors

Reimbursement

• Insurance coverage in the US for T2DM is improving, with Medicare Part D including newer GLP-1 drugs.
• Obesity coverage remains patchy; payers are cautious about high-cost drugs without long-term data.

Global Expansion

• Entry into European markets reached in late 2022 with approvals from EMA.
• China and emerging markets targeted for 2024–2025; regulatory timelines vary.

Post-Marketing Surveillance

• Focus on cardiovascular safety, given prior class concerns.
• Long-term data expected through 2024 to support broader indications.

Risks and Opportunities

Risks

• Competition intensifies as Novo Nordisk and other players develop similar or superior molecules.
• Pricing pressures and reimbursement hurdles could constrain revenue growth.
• Potential safety issues emerging could impact market acceptance.

Opportunities

• Expanded indications for cardiovascular and renal benefits.
• Partnering with payers to improve coverage.
• Capacity increases in manufacturing to meet demand for obesity treatment.

Key Takeaways

• MOUNJARO’s market entry has shifted the competitive landscape for T2DM and obesity drugs.
• Sales rapidly scaled to USD 2.2 billion in 2023, with projection to nearly USD 8 billion by 2025.
• Competitive advantage stems from its dual mechanism and superior efficacy data.
• Market challenges include pricing pressures, reimbursement barriers, and competitive responses.
• Longer-term success depends on real-world outcomes, safety profile, and expansion of indications.

FAQs

1. What distinguishes MOUNJARO from other GLP-1 receptor agonists?
MOUNJARO combines GIP and GLP-1 receptor activation, leading to greater weight reduction and glycemic control compared to compounds like semaglutide.

2. How fast is MOUNJARO gaining market share?
Within six months of launch, it achieved USD 400 million in sales and is projected to reach a 15% share of the GLP-1 market in 2023.

3. What are the primary growth drivers for MOUNJARO sales?
Efficacy in weight loss, expanding approval for obesity treatment, and increased insurance coverage.

4. What are key risks associated with MOUNJARO’s financial trajectory?
Intense competition, reimbursement challenges, and long-term safety data uncertainties.

5. Are there upcoming regulatory decisions that could impact MOUNJARO?
Yes. Approvals in additional countries, new indication submissions, and cardiovascular safety data releases influence future growth.

---

References

[1] Eli Lilly. (2023). Q2 Earnings Call.
[2] Market Research Future. (2022). Global GLP-1 Receptor Agonists Market.
[3] IQVIA. (2023). Pharmaceutical Market Dynamics.
[4] FDA. (2022). MOUNJARO (tirzepatide) approval documentation.
[5] EMA. (2022). MOUNJARO marketing authorization.